Jurnista (Hydromorphone Hydrochloride)

• Hydromorphone acts on the mu‑opioid receptor pathway to provide potent analgesia for severe pain conditions.
• Acute postoperative pain: delivers rapid pain relief to facilitate postoperative recovery.
• Cancer‑related pain: offers strong opioid control when other analgesics fail to provide adequate relief.
• Chronic severe non‑cancer pain: manages persistent pain when alternative therapies are insufficient.

• Hydromorphone Hydrochloride binds selectively to mu‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that reduce neuronal excitability and suppress the transmission of nociceptive signals. This receptor activation also modulates descending pain pathways, producing both analgesia and sedation while decreasing the perception of pain.

Hydromorphone may cause a range of adverse reactions, from mild to life‑threatening. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects

• Nausea: feeling of sickness often accompanied by an urge to vomit.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or fatigue.
• Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be fatal.
• Severe hypotension: marked drop in blood pressure causing dizziness or fainting.
• Addiction or dependence: potential for misuse and withdrawal symptoms.
• Serotonin syndrome: rare but serious condition when combined with serotonergic agents.
• Anaphylaxis: severe allergic reaction with rash, swelling, and airway compromise.

• Before prescribing Hydromorphone, clinicians should evaluate patient‑specific risk factors and monitor for safety concerns.
• Assess respiratory function: monitor breathing rate and oxygen saturation regularly.
• Evaluate renal and hepatic function: adjust therapy if organ impairment is present.
• Screen for substance‑use history: consider risk of dependence and misuse.
• Avoid use in severe asthma or COPD: heightened risk of respiratory depression.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Hydromorphone can interact with several drug classes, requiring careful assessment to prevent adverse outcomes.

Major Interactions (Avoid)

• Concomitant opioids: additive risk of respiratory depression.
• Benzodiazepines: synergistic central nervous system depression.
• MAO inhibitors: potential for serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase hydromorphone plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect.
• Anticholinergics: can exacerbate constipation.
• Alcohol: additive CNS depression, requiring dose adjustment.